Pemetrexed for the treatment of non-small-cell lung cancer

Expert Review of Anticancer Therapy

Volumn 9, Issue 9, 2009, Pages 1195-1209

  Manegold, Christian ^a   Schmid Bindert, Gerald ^a   Pilz, Lothar R ^b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Antifolate; Non small cell lung cancer; Non squamous cell histology; Pemetrexed; Thymidylate synthase; Treatment by histology

Indexed keywords

AXITINIB; BEVACIZUMAB; BORTEZOMIB; CARBOPLATIN; CETUXIMAB; CISPLATIN; CORTICOSTEROID; CYANOCOBALAMIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOCETAXEL; DOXORUBICIN; ENZASTAURIN; EPIRUBICIN; ERLOTINIB; FOLIC ACID; GEMCITABINE; IRINOTECAN; LAPATINIB; LOMETREXOL; NAVELBINE; OXALIPLATIN; PACLITAXEL; PEMETREXED; PLACEBO; SORAFENIB; SUNITINIB; UNINDEXED DRUG; VANDETANIB; VINFLUNINE;

ALOPECIA; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL TRIAL; DIARRHEA; DOSE RESPONSE; DRUG CLEARANCE; DRUG COMPETITION; DRUG DISTRIBUTION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG FATALITY; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG STRUCTURE; DRUG TARGETING; DRUG TOLERABILITY; ENZYME INHIBITION; FATIGUE; FEBRILE NEUTROPENIA; FOLIC ACID DEFICIENCY; GASTROINTESTINAL SYMPTOM; GRANULOCYTOPENIA; HEMOPTYSIS; HUMAN; HYPERTENSION; INFECTION; KIDNEY DYSFUNCTION; LEUKOPENIA; LIVER DYSFUNCTION; LIVER TOXICITY; LOADING DRUG DOSE; LUNG NON SMALL CELL CANCER; LYMPHOCYTOPENIA; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PHARMACODYNAMICS; PLEURA MESOTHELIOMA; REPEATED DRUG DOSE; REVIEW; SIDE EFFECT; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT; VITAMIN SUPPLEMENTATION; WEAKNESS;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS AS TOPIC; DRUG DELIVERY SYSTEMS; GLUTAMATES; GUANINE; HUMANS; LUNG NEOPLASMS;

EID: 70350647432     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/ERA.09.97     Document Type: Review

References (109)

1. Bunn PA Jr, Thatcher N. Systemic treatment for advanced (stage IIIb/IV) non-small cell lung cancer: more treatment options; more things to consider. Introduction. Oncologist 13(Suppl. 1), 1-4 (2008). • An excellent overview of systemic treatment in advanced non-small-cell lung cancer.
2. Stinchcombe TE, Socinski MA. Considerations for second-line therapy of non-small cell lung cancer. Oncologist 13(Suppl. 1), 28-36 (2008).
3. Shih C, Chen VJ, Gossett LS et al. LY231514, a pyrrolo[2,3-d]pyrimidine- based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res. 57(6), 1116-1123 (1997).
4. Britten CD, Izbicka E, Hilsenbeck S et al. Activity of the multitargeted antifolate LY231514 in the human tumor cloning assay. Cancer Chemother. Pharmacol. 44(2), 105-110 (1999). (Pubitemid 29297055)
5. Vogelzang NJ, Rusthoven JJ, Symanowski J et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J. Clin. Oncol. 21(14), 2636-2644 (2003). (Pubitemid 46606305)
6. Hanauske A, Chen V, Paoletti P, Niyikiza C. Pemetrexed disodium: a novel antifolate clinically active against multiple solid tumors. Oncologist 6(4), 363-373 (2001). (Pubitemid 32816541)
7. Rinaldi DA, Kuhn JG, Burris HA et al. A Phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation. Cancer Chemother. Pharmacol. 44(5), 372-380 (1999).
8. Ouellet D, Periclou AP, Johnson RD et al. Population pharmacokinetics of pemetrexed disodium (ALIMTA) in patients with cancer. Cancer Chemother. Pharmacol. 46, 227-234 (2000). (Pubitemid 30728657)
9. Nakagawa K, Kudoh S, Matsui K et al. A Phase I study of pemetrexed (LY231514) supplemented with folate and vitamin B12 in Japanese patients with solid tumours. Br. J. Cancer 95, 677-682 (2006). (Pubitemid 44373481)
10. Thödtmann R, Depenbrock H, Dumez H et al. Clinical and pharmacokinetic Phase I study of multitargeted antifolate (LY231514) in combination with cisplatin. J. Clin. Oncol. 17, 3009-3016 (1999). (Pubitemid 29218034)
11. Takimoto CH, Hammond-Thelin LA, Latz JE et al. Phase I and pharmacokinetic study of pemetrexed with high-dose folic acid supplementation or multivitamin supplementation in patients with locally advanced or metastatic cancer. Clin. Cancer Res. 13(9), 2675-2683 (2007).
12. Rinaldi DA, Burris HA, Dorr FA et al. Initial Phase I evaluation of the novel thymidylate synthase inhibitor, LY231514, using the modified continual reassessment method for dose escalation. J. Clin. Oncol. 13(11), 2842-2850 (1995).
13. McDonald AC, Vasey PA, Adams L et al. A Phase I and pharmacokinetic study of LY231514, the multitargeted antifolate. Clin. Cancer Res. 4(3), 605-610 (1998). (Pubitemid 28193558)
14. Cripps C, Burnell M, Jolivet J et al. Phase II study of first-line LY231514 (multi-targeted antifolate) in patients with locally advanced or metastatic colorectal cancer: an NCIC Clinical Trials Group study. Ann. Oncol. 10(10), 1175-1179 (1999). (Pubitemid 29533566)
15. Rusthoven J, Eisenhauer E, Butts C et al. Multitargeted antifolate, LY231514, as first-line chemotherapy for patients with advanced non-small-cell lung cancer: a Phase II study. J. Clin. Oncol. 17, 1194-1199 (1999). (Pubitemid 29162943)
16. Clarke SJ, Abratt R, Goedhals L, Boyer MJ, Millward MJ, Ackland SP. Phase II trial of pemetrexed disodium (ALIMTA, LY231514) in chemotherapy-naive patients with advanced non-small-cell lung cancer. Ann. Oncol. 13(5), 737-741 (2002). (Pubitemid 34567380)
17. Smit EF, Mattson K, von Pawel J, Manegold C, Clarke S, Postmus PE. ALIMTA® (pemetrexed disodium) as second-line treatment of non-small-cell lung cancer: a Phase II study. Ann. Oncol. 14, 455-460 (2003). (Pubitemid 36367425)
18. Manegold C, Gatzemeier U, von Pawel J et al. Front-line treatment of advanced non-small-cell lung cancer with MTA (LY231514, pemetrexed disodium, ALIMTATM) and cisplatin: a multicenter Phase II trial. Ann. Oncol. 11(4), 435-440 (2000). (Pubitemid 30333546)
19. Shepherd FA, Dancey J, Arnold A et al. Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced nonsmall cell lung carcinoma. A study of the National Cancer Institute of Canada Clinical Trials Group. Cancer 92(3), 595-600 (2001). (Pubitemid 32735195)
20. Niyikiza C, Baker SD, Seitz DE et al. Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy. Mol. Cancer Ther. 1(7), 545-552 (2002).
21. Nelson R, Butler F, Dugan W Jr, Davisland C, Stone M, Dyke R. Phase I clinical trial of LY264618 (dideazatetrahydrofolic acid; DDATHF). Proc. Am. Soc. Clin. Oncol. 9, 76 (1990).
22. Alati T, Worzalla JF, Shih C et al. Augmentation of the therapeutic activity of lometrexol [(6-R)5,10-dideazatetrahydrofolate] by oral folic acid. Cancer Res. 56(10), 2331-2335 (1996). (Pubitemid 26154082)
23. Bunn P, Paoletti P, Niyikiza C et al. Vitamin B12 and folate reduce toxicity of Alimta™ (pemetrexed disodium, LY231514, MTA), a novel antifolate/antimetabolite. Proc. Am. Soc. Clin. Oncol. 20, (2001) (Abstract 300).
24. Hanna N, Shepherd FA, Fossella FV et al. Randomized Phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J. Clin. Oncol. 22(9), 1589-1597 (2004). (Pubitemid 41079796)
25. Pujol JL, Paul S, Chouaki N et al. Survival without common toxicity criteria grade 3/4 toxicity for pemetrexed compared with docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC): a risk-benefit analysis. J. Thorac. Oncol. 2(5), 397-401 (2007). (Pubitemid 47181693)
26. Camps C, Massuti B, Jiménez A et al. Randomized Phase III study of 3-weekly versus weekly docetaxel in pretreated advanced non-small-cell lung cancer: a Spanish Lung Cancer Group trial. Ann. Oncol. 17, 467-472 (2006). (Pubitemid 43329585)
27. Schuette W, Nagel S, Blankenburg T et al. Phase III study of second-line chemotherapy for advanced non-small-cell lung cancer with weekly compared with 3-weekly docetaxel. J. Clin. Oncol. 23, 8389-8395 (2005). (Pubitemid 46260234)
28. Gridelli C, Gallo C, Di Maio M et al. A randomised clinical trial of two docetaxel regimens (weekly vs 3 week) in the second-line treatment of non-small-cell lung cancer. The DISTAL 01 study. Br. J. Cancer 91, 1996-2004 (2004).
29. Gervais R, Ducolone A, Breton JL et al. Phase II randomised trial comparing docetaxel given every 3 weeks with weekly schedule as second-line therapy in patients with advanced non-small-cell lung cancer (NSCLC). Ann. Oncol. 16, 90-96 (2005). (Pubitemid 40124484)
30. Lilenbaum R, Rubin M, Samuel J et al. A Phase II randomized trial of docetaxel weekly or every 3 weeks in elderly and/or poor performance status (PS) patients (pts) with advanced non-small-cell lung cancer (NSCLC). J. Clin. Oncol. 22(14 Suppl.), 7057 (2004).
31. Quoix E, Lebeau B, Depierre A et al. Randomised, multicentre Phase II study assessing two doses of docetaxel (75 or 100 mg/m2) as second-line monotherapy for non-small-cell lung cancer. Ann. Oncol. 15, 38-44 (2004). (Pubitemid 38139601)
32. Fossella FV, DeVore R, Kerr RN et al. Randomized Phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J. Clin. Oncol. 18, 2354-2362 (2000). (Pubitemid 30415821)
33. Shepherd FA, Dancey J, Ramlau R et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J. Clin. Oncol. 18, 2095-2103 (2000). (Pubitemid 30324363)
34. de Marinis F, Grossi F. Clinical evidence for second- and third-line treatment options in advanced non-small cell lung cancer. Oncologist 13(Suppl. 1), 14-20 (2008).
35. de Marinis F, De Santis S, De Petris L. Second-line chemotherapy for non-small cell lung cancer. Ann. Oncol. 17(Suppl. 5), v68-v71 (2006). (Pubitemid 43985209)
36. Monnerat C, Le Chevalier T. Review of the pemetrexed and gemcitabine combination in patients with advanced-stage non-small cell lung cancer. Ann. Oncol. 17(Suppl. 5), v86-v90 (2006). (Pubitemid 43985213)
37. Scagliotti GV, Kortsik C, Dark GG et al. Pemetrexed combined with oxaliplatin or carboplatin as first-line treatment in advanced non-small cell lung cancer: a multicenter, randomized, Phase II trial. Clin. Cancer Res. 11(2 Pt 1), 690-696 (2005). (Pubitemid 40116896)
38. Zinner RG, Fossella FV, Gladish GW et al. Phase II study of pemetrexed in combination with carboplatin in the first-line treatment of advanced nonsmall cell lung cancer. Cancer 104(11), 2449-2456 (2005).
39. Treat J, Bonomi P, McCleod M et al. Administration of pemetrexed immediately following gemcitabine as front-line therapy in advanced non-small cell lung cancer: A Phase II trial. Lung Cancer 53(1), 77-83 (2006). (Pubitemid 43831365)
40. Stathopoulos GP, Dimitroulis J, Toubis M et al. Pemetrexed combined with paclitaxel in patients with advanced or metastatic non-small-cell lung cancer: a Phase I-II trial. Lung Cancer 57(1), 66-71 (2007). (Pubitemid 46843342)
41. Weiss GJ, Langer C, Rosell R et al. Elderly patients benefit from second-line cytotoxic chemotherapy: a subset analysis of a randomized Phase III trial of pemetrexed compared with docetaxel in patients with previously treated advanced non-small-cell lung cancer. J. Clin. Oncol. 24(27), 4405-4411 (2006). (Pubitemid 46630978)
42. Weiss GJ, Rosell R, Fossella F et al. The impact of induction chemotherapy on the outcome of second-line therapy with pemetrexed or docetaxel in patients with advanced non-small-cell lung cancer. Ann. Oncol. 18(3), 453-460 (2007). (Pubitemid 46359622)
43. Bearz A, Garassino I, Cavina R et al. Pemetrexed single agent in previously treated non-small cell lung cancer: a multi-institutional observational study. Lung Cancer 60(2), 240-245 (2008). (Pubitemid 351609151)
44. Cullen MH, Zatloukal P, Sörenson S et al. A randomized Phase III trial comparing standard and high-dose pemetrexed as second-line treatment in patients with locally advanced or metastatic non-small-cell lung cancer. Ann. Oncol. 19(5), 939-945 (2008). (Pubitemid 351627311)
45. Grønberg BH, Bremnes R, Aasebø U et al. Pemetrexed + carboplatin versus gemcitabine + carboplatin in the treatment of stage IIIB/IV non-small cell lung cancer. J. Clin. Oncol. 25(18S), (2007) (Abstract 7517).
46. Scagliotti GV, Parikh P, von Pawel J et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J. Clin. Oncol. 26(21), 3543-3551 (2008). •• First prospective Phase III study in NSCLC to show survival differences based on histologic type.
47. Peterson P, Park K, Fossella F, Gatzemeier U, John W, Scagliotti G. Is pemetrexed more effective in patients with non-squamous histology? A retrospective analysis of a Phase III trial of pemetrexed vs docetaxel in previously treated patients with advanced nonsmall cell lung cancer (NSCLC). Eur. J. Cancer Suppl. 5(4), 363 (2007). •• Important trial in establishing the differential efficacy of pemetrexed and docetaxel in squamous- and non-squamous-type NSCLC. However, it must be noted that it has yet to be published as a complete paper and the first author works for Eli Lilly & Co.
48. Ohe Y, Ichinose Y, Nakagawa K et al. Efficacy and safety of two doses of pemetrexed supplemented with folic acid and vitamin B12 in previously treated patients with non-small cell lung cancer. Clin. Cancer Res. 14(13), 4206-4212 (2008).
49. Peng G, Zinner RG, Wang Y et al. Comparison of patient outcomes stratified by histology among pemetrexed (P)-treated patients (pts) with stage IIIB/IV non-small cell lung cancer (NSCLC) in two Phase II trials. J. Clin. Oncol. 26(Suppl.), (2008) (Abstract 8096).
50. Ceppi P, Volante M, Savlozzi S et al. Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase. Cancer 107(7), 1579-1596 (2006). (Pubitemid 44546920)
51. Grønberg BH, Bremnes RM, Aasebø U et al. A prospective Phase II study: high-dose pemetrexed as second-line chemotherapy in small-cell lung cancer. Lung Cancer 63(1), 88-93 (2009).
52. Ceppi P, Volante M, Ferrero A et al. Thymidylate synthase expression in gastroenteropancreatic and pulmonary neuroendocrine tumors. Clin. Cancer Res. 14(4), 1059-1064 (2008). (Pubitemid 351302551)
53. Hanauske AR, Eismann U, Oberschmidt O et al. In vitro chemosensitivity of freshly explanted tumor cells to pemetrexed is correlated with target gene expression. Invest. New Drugs. 25(5), 417-423 (2007). (Pubitemid 47222911)
54. van den Bogaert DP, Pouw EM, van Wijhe G et al. Pemetrexed maintenance therapy in patients with malignant pleural mesothelioma. J. Thorac. Oncol. 1(1), 25-30 (2006).
55. Ciuleanu TE, Brodowicz T, Belani CP et al. Maintenance pemetrexed plus best supportive care (BSC) versus placebo plus BSC: a Phase III study. J. Clin. Oncol. 26(20 Suppl.), (2008) (Abstract 8011).
56. Belani CP, Brodowicz T, Ciuleanu T et al. Maintenance pemetrexed (Pem) plus best supportive care (BSC) versus placebo (Plac) plus BSC: A randomized Phase III study in advanced non-small cell lung cancer (NSCLC). J. Clin. Oncol. 27, 18(Suppl.), (2009) (Abstract CRA8000).
57. Patel JD, Hensing TA, Rademaker F et al. Pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for advanced non-squamous non-small cell lung cancer (NSCLC). J. Clin. Oncol. 26(Suppl), (2008) (Abstract 8044).
58. Waples JM, Auerbach M, Boccia R, Wiggans RG, Steis R; International Oncology Network. A Phase II study of oxaliplatin and pemetrexed plus bevacizumab in advanced non-squamous non-small cell lung cancer. J. Clin. Oncol. 25(18S), (2007) (Abstract 18025).
59. Heist RS, Fidias P, Huberman M et al. A Phase II study of oxaliplatin, pemetrexed, and bevacizumab in previously treated advanced non-small cell lung cancer. J. Thorac. Oncol. 3(10), 1153-1158 (2008).
60. Li T, Ling YH, Goldman ID, Perez-Soler R. Schedule-dependent cytotoxic synergism of pemetrexed and erlotinib in human non-small cell lung cancer cells. Clin. Cancer Res. 13(11), 3413-3422 (2007). (Pubitemid 46944930)
61. Davies AM, Ho C, Lara PN, Mack P, Gumerlock PH, Gandara DR. Pharmacodynamic separation of EGFR TKIs and chemotherapy in NSCLC. Clin. Lung Cancer 7(6), 385-388 (2006).
62. Giovannetti E, Lemos C, Tekle C et al. Molecular mechanisms underlying the synergistic interaction of erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, with the multitargeted antifolate pemetrexed in non-small-cell lung cancer cells. Mol. Pharmacol. 73(4), 1290-1300 (2008).
63. Ranson M, Reck M, Anthoney A et al. A Phase Ib, dose-finding study of erlotinib in combination with pemetrexed in patients with advanced (stage IIIb/IV) non-small-cell lung cancer (NSCLC): a preliminary analysis of the BP18193 study. Eur. J. Cancer Suppl. 5, 384, (2007) (Abstract 6587).
64. Bunn PA Jr, Thatcher N. Systemic treatment for advanced (stage IIIb/IV) non-small cell lung cancer: more treatment options; more things to consider. Conclusion. Oncologist 13(Suppl. 1), 37-46 (2008). Excellent overview of systemic treatment in advanced NSCLC.
65. Tekle C, Giovannetti E, Sigmond J, Graf JR, Smid K, Peters GJ. Molecular pathways involved in the synergistic interaction of the PKC inhibitor enzastaurin with the antifolate pemetrexed in non-small cell lung cancer cells. Br. J. Cancer 99, 750-759 (2008).
66. Jalal SI, Waterhouse D, Edelman M et al. Pemetrexed plus cetuximab in patients (pts) with recurrent non-small cell lung cancer (NSCLC): a Phase I-IIa dose-ranging study from the Hoosier Oncology Group. J. Clin. Oncol. 25(18S), (2007) (Abstract 7698).
67. Langer CJ, Wakelee H, Schiller J et al. Cooperative group portfolio in locally advanced non-small-cell lung cancer: are we making progress? Clin. Lung Cancer 9(2), 85-91 (2008). (Pubitemid 351658840)
68. Vokes EE, Herndon JE 2nd, Kelley MJ et al.; Cancer and Leukemia Group B. Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III non-small-cell lung cancer: Cancer and Leukemia Group B. J. Clin. Oncol. 25(13), 1698-1704 (2007).
69. Socinski MA, Blackstock AW, Bogart JA et al. Randomized Phase II trial of induction chemotherapy followed by concurrent chemotherapy and dose-escalated thoracic conformal radiotherapy (74 Gy) in stage III non-small-cell lung cancer: CALGB 30105. J. Clin. Oncol. 26(15), 2457-2463 (2008).
70. Bischof M, Weber KJ, Blatter J, Wannenmacher M, Latz D. Interaction of pemetrexed disodium (ALIMTA, multitargeted antifolate) and irradiation in vitro. Int. J. Radiat. Oncol. Biol. Phys. 52(5), 1381-1388 (2002). (Pubitemid 34302884)
71. Brade AM, Bezjak A, MacRae R et al. A Phase I study of concurrent pemetrexed (P)/cisplatin (C)/radiation (RT) for unresectable stage IIIA/B non-small cell lung cancer (NSCLC). J. Clin. Oncol. 26(Suppl.), (2008) (Abstract 7550).
72. Seiwert TY, Connell PP, Mauer AM et al. A Phase I study of pemetrexed, carboplatin, and concurrent radiotherapy in patients with locally advanced or metastatic non-small cell lung or esophageal cancer. Clin. Cancer Res. 13, 515-522 (2007).
73. Govindan R, Bogart J, Wang X, Liu D, Kratzke RA, Vokes EE. A Phase II study of pemetrexed, carboplatin and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small cell lung cancer: CALGB 30407 - early evaluation of feasibility and toxicity. J. Clin. Oncol. 26(15S), (2008) (Abstract 7518).
74. Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon JP, Vansteenkiste J; International Adjuvant Lung Cancer Trial Collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N. Engl. J. Med. 350, 351-360 (2004).
75. Winton T, Livingston R, Johnson D et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N. Engl. J. Med. 352, 2589-2597 (2005). (Pubitemid 41400930)
76. Douillard J, Rosell R, De Lena M et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol. 7, 719-727 (2006). (Pubitemid 44283661)
77. Pisters KM, Le Chevalier T. Adjuvant chemotherapy in completely resected non-small cell lung cancer. J. Clin. Oncol. 23, 3270-3278 (2005). (Pubitemid 40254918)
78. Alam N, Shepherd FA, Winton T et al. Compliance with postoperative adjuvant chemotherapy in non-small cell lung cancer. An analysis of National Cancer Institute of Canada and Intergroup Trial JBR10 and review of the literature. Lung Cancer 47, 385-394 (2005). (Pubitemid 40248743)
79. Schmid-Bindert G, Chemaissani A, Fischer JR et al. Pemetrexed in combination with cisplatin or carboplatin as adjuvant chemotherapy in early-stage NSCLC. J. Clin. Oncol. 27, 15(Suppl.), (2009) (Abstract 7565).
80. Kreuter M, Vansteenkiste J, Griesinger F et al. Trial on refinement of early stage non-small cell lung cancer. Adjuvant chemotherapy with pemetrexed and cisplatin versus vinorelbine and cisplatin: the TREAT protocol. BMC Cancer 7, 77 (2007). (Pubitemid 46863631)
81. Eli Lilly and Company. Alimta Summary of Product Characteristics http://emc.medicines.org.uk/emc/industry/default.asp?page=displaydoc. asp&documentid=15513 (Accessed July 2008)
82. A study for patients with non-squamous non-small cell lung cancer www.clinicaltrials.gov/ct2/show/NCT00609518 (Accessed June 2009)
83. Socinski MA. Lung Cancer - local-regional and adjuvant therapy (discussion). ASCO Annual Meeting 2008, oral presentation www.asco.org/ASCOv2/ MultiMedia/Virtual+Meeting?vmview=vm-session-presentations-view&confID= 55&sessionID=371104 (Accessed June 2009)
84. US FDA Center for Drug Evaluation and Research. Alimta (pemetrexed for injection) Information. 2004 www.fda.gov/CDER/DRUG/infopage/alimta/default.htm (Accessed January 2008)
85. European Medicines Agency. Alimta European Public Assessment Report (EPAR). Revision 9 www.emea.europa.eu/humandocs/Humans/EPAR/alimta/alimta.htm (Accessed July 2008)
86. A study of induction and maintenance treatment of advanced non-squamous non small cell lung cancer www.clinicaltrials.gov/ct2/show/NCT00789373 (Accessed June 2009)
87. Pemetrexed and best supportive care versus placebo and best supportive care in non-small cell lung cancer www.clinicaltrials.gov/show/NCT00102804 (Accessed July 2008)
88. A study comparing two different chemotherapy regimens, in patients with advanced non-squamous non-small cell lung cancer www.clinicaltrials.gov/show/ NCT00606021 (Accessed July 2008)
89. A study of pemetrexed, carboplatin and bevacizumab in patients with nonsquamous non-small cell lung cancer www.clinicaltrials.gov/ct2/show/ NCT00762034 (Accessed June 2009)
90. Study of pemetrexed versus pemetrexed + erlotinib as treatment of non small cell lung cancer www.clinicaltrials.gov/ct2/show/NCT00447057 (Accessed June 2009)
91. Pemetrexed disodium with or without erlotinib in treating patients with stage IIIB or stage IV non-small cell lung cancer that responded to previous erlotinib www.clinicaltrials.gov/ct2/show/NCT00660816 (Accessed June 2009)
92. Trial of pemetrexed versus erlotinib in pretreated patients with non small cell lung cancer (NSCLC) www.clinicaltrials.gov/ct2/show/NCT00440414 (Accessed June 2009)
93. First line chemotherapy treatment of advanced NSCLC www.clinicaltrials. gov/show/NCT00308750 (Accessed July 2008)
94. A study of induction and maintenance treatment of advanced or metastatic non squamous non-small cell lung cancer www.clinicaltrials.gov/ct2/show/ NCT00867009 (Accessed June 2009)
95. Docetaxel or pemetrexed with or without cetuximab in patients with recurrent or progressive non-small cell lung cancer www.clinicaltrials.gov/ct2/ show/NCT00095199 (Accessed June 2009)
96. Efficacy study comparing ZD6474 in combination with pemetrexed and pemetrexed alone in 2nd line NSCLC patients (ZEAL) www.clinicaltrials.gov/ct2/ show/NCT00418886 (Accessed June 2009)
97. A two arm Phase I dose escalation trial of vinflunine with erlotinib or pemetrexed in refractory solid tumors www.clinicaltrials.gov/ct/show/NCT00320073 (Accessed July 2008)
98. A study to find the best dose of SU011248 when given with pemetrexed, pemetrexed and cisplatin or pemetrexed and carboplatin in patients with advanced solid tumors www.clinicaltrials.gov/ct2/show/NCT00528619 (Accessed June 2009)
99. Pemetrexed and/or sunitinib as second-line therapy in treating patients with stage IIIB or stage IV non-small cell lung cancer www.clinicaltrials.gov/ ct2/show/NCT00698815 (Accessed June 2009)
100. Evaluation of the efficacy of the combination of axitinib with pemetrexed and cisplatin in the treatment of non-squamous non-small cell lung cancer www.clinicaltrials.gov/ct2/show/NCT00768755 (Accessed June 2009)
101. MK-0646 insulin growth factor 1 receptor antibody in stage IIIb or IV metastatic non-squamous lung cancer (IMPACT) www.clinicaltrials.gov/ct2/show/ NCT00799240 (Accessed June 2009)
102. Pemetrexed disodium with or without sorafenib as second-line therapy in treating patients with stage IIIB or stage IV non-small cell lung cancer www.clinicaltrials.gov/ct2/show/NCT00454194 (Accessed June 2009)
103. Bortezomib (Velcade) + pemetrexed (Alimta) in advanced NSCLC www.clinicaltrials.gov/ct2/show/NCT00516100 (Accessed June 2009)
104. Lume Lung 2 : BIBF 1120 Plus pemetrexed compared to placebo plus pemetrexed in 2nd line nonsquamous NSCLC www.clinicaltrials.gov/ct2/show/ NCT00806819 (Accessed June 2009)
105. A Phase II trial of lapatinib (TYKERB) + pemetrexed (ALIMTA) versus pemetrexed in advanced non small cell lung cancer www.clinicaltrials.gov/ct2/ show/NCT00528281 (Accessed June 2009)
106. Study of pazopanib and pemetrexed in advanced non-small cell lung cancer www.clinicaltrials.gov/ct2/show/NCT00871403 (Accessed June 2009)
107. Chemotherapy and radiation in treating patients with stage 3 non-small cell lung cancer (PROCLAIM) www.clinicaltrials.gov/ct2/show/NCT00686959 (Accessed June 2009)
108. Feasibility study of pemetrexed in combination with cisplatin or carboplatin as adjuvant treatment of non small cell lung cancer www.clinicaltrials.gov/ct/show/NCT00269152 (Accessed January 2009)
109. Trial on refinement of early stage lung cancer adjuvant therapy www.clinicaltrials.gov/ct/show/NCT00349089 (Accessed January 2009)